# Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Source: https://onco.cc/trials/nct06640530/  
OnCo record `nct06640530` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nivolumab in melanoma, run by Biocad, active and no longer recruiting.

## Summary

Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin is a phase 3 interventional study registered as NCT06640530 by Biocad, with 392 participants planned, started 2024-03-21 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-263, Opdivo. Conditions listed: Advanced Melanoma, Melanoma (Skin). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06640530
- Phase: 3
- Setting: A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
- Sponsor: Biocad
- Enrolled: 392

## Sources

- ClinicalTrials.gov NCT06640530: https://clinicaltrials.gov/study/NCT06640530

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct06640530.json